Ideal cardiovascular health metrics and the risk of nonalcoholic fatty liver disease in Korean adults

Clinical Hypertension

Table 1 Diagnosis of nonalcoholic fatty liver disease in the study

Variable	Index	Formula	Cut-point
Biomarker	Fatty liver index	\(1/((1+exp(-x)))\times 100,\)	≥ 30
	Fatty liver index	\(\begin{array}{c}x= 0.953 \times {log}_{e} \left(triglycerides\right)+ 0.139 \times BMI + 0.718 \times {log}_{e} \left(\gamma -glutamyl-transferase\right)\\ + 0.053 \times \left(waist\ circumference\right)- 15\end{array}\)
	NAFLD liver fat score^a)	\(\begin{array}{c}-2.89 + 1.18 \times metabolic\ syndrome \left(yes =1, no =0\right)+ 0.45\times diabetes \left(yes =2, no =0\right)\\ + 0.15 \times (fasting\ insulin) + 0.04 \times AST + 0.94 \times \frac{AST}{ALT}\end{array}\)	> –0.64
	Hepatic steatosis index ^a)	\(8\times \frac{ALT}{AST}+BMI \left(+2, if\ diabetes; +2, if female\right)\)	> 36
Image using quantitative computed tomography	Liver-to-spleen ratio	\(The\ mean\ value\ of\ liver\ ROI\ (HU)^\text{b)}/\ the\ mean\ value\ of\ spleen\ ROI\ (HU)\)	< 1.0

BMI Body mass index, NAFLD Nonalcoholic fatty liver disease, AST Aspartate aminotransferase, ALT Alanine aminotransferase, ROI Region of interest, HU Hounsfield unit
^a)Used for the sensitivity analyses
^b)The values measured from one ROI at baseline examination and the average of the values measured from three ROIs at follow-up study were respectively used

ISSN: 2056-5909